May 25, 2021 / 06:00PM GMT
Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
Well, good afternoon, and thank you, everyone for joining the virtual UBS Global Healthcare Conference. I'm Colin Bristow. I'm one of the biotech analysts here at UBS. And it's my pleasure to have with us today, BioXcel. Speaking on behalf of the company, we have Will Kane, the Chief Commercial Officer, and later for Q&A, we'll have Vince O'Neill, the Chief Medical Officer. So Will and Vince, thank you for joining us today.
Before we start, if anyone has a question, there is a question function available within this video app or feel free you e-mail me directly at [email protected] and I can try and fill the question for you.
And with that, Will, I'll hand it over to you now. Thanks.
William P. Kane - BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer
Sure. Thank you so much, Colin, and thank you for the opportunity this afternoon to talk about BioXcel Therapeutics. It's a great opportunity for me to share the evolving story and the key
BioXcel Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot